Reata Expects to Double Staff by the End of 2020

The publicly-traded company will use the funds to register and commercialize medications for two rare genetic diseases in the U.S and across the globe.

Plano-based drug developer Reata Pharmaceuticals Inc. raised more than $505 million in a stock sale Monday to speed its transition from a clinical-stage biotech startup to a company that makes treatments for life-threatening diseases. 

Click here for more details.